The PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with pre-diabetes (PROPELS)

Conditions

Diabetes Nutritional, Metabolic, Endocrine Diabetes mellitus

Laura Heathcote, Daniel Pollard, Alan Brennan, Melanie J. Davies, Helen Eborall et al. (15 authors)

BMJ Open Diabetes Research & Care2024-03-011 citations

10.1136/bmjdrc-2023-003516

Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT

Kamlesh Khunti, Simon J. Griffin, Alan Brennan, Helen Dallosso, Melanie J. Davies et al. (17 authors)

Health Technology Assessment2021-12-0130 citations

10.3310/hta25770

Differences in objectively measured physical activity and sedentary behaviour between white Europeans and south Asians recruited from primary care: cross-sectional analysis of the PROPELS trial.

Biddle GJH, Edwardson CL, Rowlands AV, Davies MJ, Bodicoat DH, Hardeman W, Eborall H, Sutton S, Griffin S, Khunti K, Yates T.

2019-01-2128 citations

10.1186/s12889-018-6341-5

A Text-Messaging and Pedometer Program to Promote Physical Activity in People at High Risk of Type 2 Diabetes: The Development of the PROPELS Follow-On Support Program

Katie Morton, Stephen Sutton, Wendy Hardeman, Jacqui Troughton, Tom Yates et al. (9 authors)

JMIR mhealth and uhealth2015-12-1565 citations

10.2196/mhealth.5026

PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial.

Yates T, Griffin S, Bodicoat DH, Brierly G, Dallosso H, Davies MJ, Eborall H, Edwardson C, Gillett M, Gray L, Hardeman W, Hill S, Morton K, Sutton S, Troughton J, Khunti K.

2015-07-0219 citations

10.1186/s13063-015-0813-z

Interventions

Control Group Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes mellitus (T2DM) and cardiovasular disease (CVD) and how physical activity can be used t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 40-74 years or 25-74 years if South Asian 2. Diagnosed with Impaired Glucose Regulation (IGR) within the last 5 years

Exclusion criteria

Exclusion criteria: 1. Due to the nature of the intervention those unable to undertake ambulatory based activity will be excluded 2. Those diagnosed with diabetes 3. With screen detected diabetes at baseline 4. Pregnant women 6. Those with normal glycaemia with no previous record of IGR in the previous 5 years

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 12/07/2019: Change in ambulatory activity (steps/day) between baseline and 48 months, assessed by accelerometer (Actigraph GT3X+). Acceleration data are captured and stored at 100 Hz. Data processing will be undertaken on a commercially available analysis tool (KineSoft). Data will be integrated into 60-second epochs. At least 3 valid days of wear will be required, with a valid day defined as at least 10 hours of wear. Non-wear time will be determined by 1 hour or more of consecutive zero counts Previous primary outcome measure: Change in ambulatory activity (steps per day) at 48 months	—

Measure

Time frame

Current primary outcome measure as of 12/07/2019: Change in ambulatory activity (steps/day) between baseline and 48 months, assessed by accelerometer (Actigraph GT3X+). Acceleration data are captured and stored at 100 Hz. Data processing will be undertaken on a commercially available analysis tool (KineSoft). Data will be integrated into 60-second epochs. At least 3 valid days of wear will be required, with a valid day defined as at least 10 hours of wear. Non-wear time will be determined by 1 hour or more of consecutive zero counts Previous primary outcome measure: Change in ambulatory activity (steps per day) at 48 months

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 12/07/2019: 1. Change in ambulatory activity (steps/day) between baseline and 12 months assessed by accelerometer (Actigraph GT3X+) 2. Assessed by accelerometer between baseline and 12 months, and between baseline and 48 months: 2.1 Number of censored steps/day (i.e. steps taken above an intensity used to distinguish between purposeful and incidental ambulation) 2.2 Time spent sedentary (mins) 2.3 Time spent in light physical activity (mins) 2.4 Time spent in moderate-to-vigorous physical activity (mins) 2.5 Compliance with recommendation to undertake at least 21.4 minutes/day (150 mins /week) of moderate-to-vigorous intensity physical activity in bouts of at least 10 minutes 2.6 Compliance with recommendation to undertake at least 21.4 minutes/day (150 mins/week) of moderate-to-vigorous intensity physical activity without bout restriction 3. Assessed by activPAL3 between baseline and 12 months, and between baseline and 48 months: 3.1 Time spent sitting or lying down (mins) 3.2 Time spent standing (mins) 3.3 Time spent walking (mins) 4. Assessed by Recent Physical Activity Questionnaire (RPAQ) between baseline and 12 months, and between baseline and 48 months: 4.1 Overall physical activity expenditure (kJ/day) 4.2 Time sedentary (mins), in light (mins), moderate-to-vigorous (mins) intensity physical activity 5. Main biochemistry outcomes between baseline and 12 months, and between baseline and 48 months: 5.1 HbA1c (mmol/mol) 5.2 HbA1c (%) 5.3 Total cholesterol (mmol/l) 5.4 HDL cholesterol (mmol/l) 5.5 LDL cholesterol (mmol/l) 5.6 Triglycerides (mmol/l) 5.7 Vitamin D (nmol/l) 6. Other biochemistry outcomes between baseline and 12 months, and between baseline and 48 months: 6.1 Sodium (mmol/l) 6.2 Potassium (mmol/l) 6.3 Urea (mmol/l) 6.4 Estimated glomerular filtration rate (eGFR; ml/min/1.73m2) 6.5 Total bilirubin (umol/l) 6.6 Alkaline phosphatase (IU/l) 6.7 Alanine transaminase (IU/l) 6.8 GGT (IU/l) 6.9 Urine albumin creatini	—

Measure

Time frame

Current secondary outcome measures as of 12/07/2019: 1. Change in ambulatory activity (steps/day) between baseline and 12 months assessed by accelerometer (Actigraph GT3X+) 2. Assessed by accelerometer between baseline and 12 months, and between baseline and 48 months: 2.1 Number of censored steps/day (i.e. steps taken above an intensity used to distinguish between purposeful and incidental ambulation) 2.2 Time spent sedentary (mins) 2.3 Time spent in light physical activity (mins) 2.4 Time spent in moderate-to-vigorous physical activity (mins) 2.5 Compliance with recommendation to undertake at least 21.4 minutes/day (150 mins /week) of moderate-to-vigorous intensity physical activity in bouts of at least 10 minutes 2.6 Compliance with recommendation to undertake at least 21.4 minutes/day (150 mins/week) of moderate-to-vigorous intensity physical activity without bout restriction 3. Assessed by activPAL3 between baseline and 12 months, and between baseline and 48 months: 3.1 Time spent sitting or lying down (mins) 3.2 Time spent standing (mins) 3.3 Time spent walking (mins) 4. Assessed by Recent Physical Activity Questionnaire (RPAQ) between baseline and 12 months, and between baseline and 48 months: 4.1 Overall physical activity expenditure (kJ/day) 4.2 Time sedentary (mins), in light (mins), moderate-to-vigorous (mins) intensity physical activity 5. Main biochemistry outcomes between baseline and 12 months, and between baseline and 48 months: 5.1 HbA1c (mmol/mol) 5.2 HbA1c (%) 5.3 Total cholesterol (mmol/l) 5.4 HDL cholesterol (mmol/l) 5.5 LDL cholesterol (mmol/l) 5.6 Triglycerides (mmol/l) 5.7 Vitamin D (nmol/l) 6. Other biochemistry outcomes between baseline and 12 months, and between baseline and 48 months: 6.1 Sodium (mmol/l) 6.2 Potassium (mmol/l) 6.3 Urea (mmol/l) 6.4 Estimated glomerular filtration rate (eGFR; ml/min/1.73m2) 6.5 Total bilirubin (umol/l) 6.6 Alkaline phosphatase (IU/l) 6.7 Alanine transaminase (IU/l) 6.8 GGT (IU/l) 6.9 Urine albumin creatini

—

Countries

England, United Kingdom

Outcome results

None listed